Physician profile
Chloe Khoo
NPI 1275996043
$7,201.80
in general payments reported to CMS, 2019-2025
17 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,005 · 2023: $1,916 · 2024: $1,991 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,087 · Honoraria: $810 · Grant: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,086.76 |
| Honoraria | $810.00 |
| Grant | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,545.57 | 2022-2025 | Unity, Hydrus Microstent |
| Regeneron Healthcare Solutions, INC. | $1,340.67 | 2022-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $1,284.99 | 2022-2024 | Iluvien, Yutiq |
| Apellis Pharmaceuticals, INC. | $606.13 | 2022-2025 | Syfovre |
| Regeneron Pharmaceuticals, INC. | $441.50 | 2023-2024 | Eylea, Eylea Hd |
| Abbvie INC. | $327.24 | 2023-2025 | |
| Genentech USA, INC. | $308.18 | 2023-2025 | Vabysmo, Susvimo |
| Dutch Ophthalmic, USA | $290.53 | 2024 | Tissueblue, Eva, Combined Machine |
| Eyepoint US, INC. | $238.54 | 2022-2023 | |
| Astellas Pharma US INC | $227.10 | 2023-2025 | Izervay |
| Astellas US LLC | $135.72 | 2024 | Izervay |
| Immunocore Limited | $121.41 | 2023 | Kimmtrak |
| Ani Pharmaceuticals, INC. | $110.72 | 2024-2025 | Yutiq, Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $91.78 | 2024-2025 | Acthar |
| Coherus Oncology, INC. | $76.14 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $36.77 | 2024 | Vyzulta, Miebo, Xiidra |
| Harrow Eye, LLC | $18.81 | 2024 | Triesence, Iheezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chloe Khoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.